<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04579848</url>
  </required_header>
  <id_info>
    <org_study_id>DIA2020-01</org_study_id>
    <nct_id>NCT04579848</nct_id>
  </id_info>
  <brief_title>Methotrexate in Erosive Inflammatory Hand Osteoarthritis</brief_title>
  <acronym>MERINO</acronym>
  <official_title>The Methotrexate in ERosive INflammatory Osteoarthritis (MERINO) Trial: A Randomized Placebo-controlled Trial to Investigate Clinical Efficacy and Safety of Methotrexate in Erosive Inflammatory Hand Osteoarthritis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diakonhjemmet Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Diakonhjemmet Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A placebo-controlled randomized controlled trial exploring the effect of methotrexate on&#xD;
      pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The trial will include Norwegian adult males and females with symptomatic erosive&#xD;
      inflammatory hand osteoarthritis.&#xD;
&#xD;
      Participants will be randomized 1:1 to either:&#xD;
&#xD;
        1. Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg&#xD;
           the remaining weeks (intervention group). Dosage can be reduced to as low as 10 mg if&#xD;
           higher doses are not tolerated.&#xD;
&#xD;
        2. Placebo (control group).&#xD;
&#xD;
      Both arms will receive folic acid 1mg daily.&#xD;
&#xD;
      The treatment duration for both groups is 52 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>An investigator-initiated, randomized, double-blinded, placebo-controlled, parallel-group, single-center, phase IV, superiority study, exploring the effect of methotrexate on pain, function and structural outcomes in erosive inflammatory hand osteoarthritis.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Identical placebo cannot be produced due to text, color and shape of methotrexate tablets. Thus, both placebo and methotrexate will be encapsulated to ensure blinding.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Finger pain on a visual analogue scale</measure>
    <time_frame>6 months</time_frame>
    <description>Difference in self-reported finger joint pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OMERACT-OARSI responder criteria</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Fulfillment of Outcome Measures in Rheumatology Osteoarthritis Research Society International (OMERACT-OARSI) responder criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Finger pain on a visual analogue scale</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Self-reported finger pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thumb pain on a visual analogue scale</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Self-reported thumb pain previous 48 hours on a 0-100 mm scale; higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain most painful finger joint on a visual analogue scale</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Pain most painful finger joint last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported disease activity on a visual analogue scale</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Patient-reported disease activity last 48 hours on a 0-100 mm scale; higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUSCAN</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Australian/Canadian hand index (AUSCAN), sum score 0-60, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Quality-adjusted life years (QALYs) based on the health-related utility scores measured by the generic instrument EuroQol 5 dimensions (EQ-5D), sum score 5-35, higher value indicate worse outcome, in addition to a 0-100 visual analogue scale where higher value indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant medication</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Concomitant medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender and swollen joints</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Number of tender and swollen joints (range 0-30), higher values indicate more affected joints.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grip strength</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Grip strength (in kg; using a hand dynamometer)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain sensitization</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Pain sensitization: Pressure Pain Thresholds (PPT) by digital algometer; temporal summation by punctate probes; Conditioned Pain Modulation (CPM) by blood pressure ischemic test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ultrasound</measure>
    <time_frame>Month 1, 3, 6, 9 and 12.</time_frame>
    <description>Ultrasound: number of finger joints with synovial thickening and power Doppler signals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hand diagram pain</measure>
    <time_frame>Month 6.</time_frame>
    <description>Finger pain and thumb base pain (yes/no) on hand diagram</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MHOQ</measure>
    <time_frame>Month 6.</time_frame>
    <description>Michigan Hand Outcomes Questionnaire (MHOQ) pain and physical function subscales; function subscale range 10-50, higher value indicate worse outcome; task subscale range 17-85, higher value indicate worse outcome; work subscale range 5-25, higher value indicate worse outcome; pain subscale range 10-48, higher value indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning stiffness fingers</measure>
    <time_frame>Month 6.</time_frame>
    <description>Duration of morning stiffness in finger joints in minutes, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morning stiffness thumbs</measure>
    <time_frame>Month 6.</time_frame>
    <description>Duration of morning stiffness in thumb base joints in minutes, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HADS</measure>
    <time_frame>Month 6.</time_frame>
    <description>Hospital Anxiety and Depression Scales (HADS), range 0-42, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PCS</measure>
    <time_frame>Month 6.</time_frame>
    <description>Pain Catastrophizing Scale (PCS), range 0-12, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PSQ</measure>
    <time_frame>Month 6.</time_frame>
    <description>Pain Sensitivity Questionnaire (PSQ), range 0-170, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>KOOS-12</measure>
    <time_frame>Month 6.</time_frame>
    <description>Knee injury and Osteoarthritis Outcome Score (KOOS)-12, range 12-60, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HOOS-12</measure>
    <time_frame>Month 6.</time_frame>
    <description>Hip disability and Osteoarthritis Outcome Score (HOOS)-12, range 12-60, higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographs: Kellgren Lawrence</measure>
    <time_frame>Month 6 and 12</time_frame>
    <description>Conventional radiographs: change in radiographic severity according to Kellgren-Lawrence scale, range 0-4 in each finger joints, in total 30 joints; higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographs: Verbruggen-Veys anatomical phase scoring system</measure>
    <time_frame>Month 6 and 12</time_frame>
    <description>Conventional radiographs: change in radiographic severity in finger joints according to Verbruggen-Veys anatomical phase scoring system, range 1-5 in each finger joint, in total 30 finger joints; higher value indicate worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiographs: OARSI atlas</measure>
    <time_frame>Month 6 and 12</time_frame>
    <description>Conventional radiographs: change in radiographic severity according to the Osteoarthritis Research Society International (OARSI) atlas for the presence/severity of osteophytes, joint space narrowing and erosions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble biomarkers of extracellular matrix turnover</measure>
    <time_frame>Month 6 and 12</time_frame>
    <description>Markers of collagen degradation (s-COMP, s-C1M, s-C2M, s-C3M, s-CTX1, sHA), collagen synthesis (s-proC2), aggrecan degradation (s-huARGS) and inflammation (s-calprotectin, s- vimentin, s-hsCRP and s-CRPM); Inflammatory cytokines (IL-1β, IL-1ra, IL-4, IL-6, IL-10, IL-12, IL-17, IL-18, IL-21, IFN-γ, TNF-α, VEGF, GM-CSF, CCL2, CCL3, CCL4, CXCL10) and hormones (leptin and resistin).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, maximum 12 months, in addition to 3 months after end of treatment.</time_frame>
    <description>Number of adverse events, serious adverse events, and withdrawals because of adverse events.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sub-study: biopsy of knee OA</measure>
    <time_frame>Month 6</time_frame>
    <description>Change in synovial cellular composition and gene expression with single-cell RNA sequencing analyses; subgroup analyses, n=16 patients</description>
  </other_outcome>
  <other_outcome>
    <measure>Sub-study: knee pain on a visual analogue scale</measure>
    <time_frame>Month 6</time_frame>
    <description>Self-reported knee pain previous 48 hours on a 0-100 mm scale at 6 months of treatment; higher value indicate worse outcome.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Hand Osteoarthritis</condition>
  <condition>Erosive Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methotrexate oral x 1/week; weekly starting dose 15 mg for two weeks, followed by 20 mg the remaining weeks.&#xD;
Additional Folic acid 1mg prescribed daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 capsules per week for two weeks, followed by 4 capsules the remaining weeks.&#xD;
Additional Folic acid 1mg prescribed daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate Tablets</intervention_name>
    <description>Methotrexate 2.5mg oral tablet.</description>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid 1 MG</intervention_name>
    <description>Folic acid</description>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Finger joint pain 40-80 on 0-100 visual analog scale (VAS) with insufficient pain&#xD;
             relief from, inability to tolerate or contra-indications to oral paracetamol and/or&#xD;
             NSAIDs, and hand symptoms (pain, aching, or stiffness) on most days the previous 6&#xD;
             weeks before randomization.&#xD;
&#xD;
          -  Hand OA according to the American College of Rheumatology (ACR) criteria, at least 1&#xD;
             distal (DIP) or proximal interphalangeal (PIP) joint of the 2nd-5th finger with&#xD;
             radiographic pre-erosive (J-phase) or erosive disease (E-phase) according to the&#xD;
             Verbruggen-Veys anatomical phase system, and at least two DIP/PIP joints with power&#xD;
             Doppler signal of at least grade 1 or grey-scale synovitis of at least grade 2 on&#xD;
             ultrasound.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        A full list of the exclusion criteria for this study comprised the following:&#xD;
&#xD;
          -  Contraindications to methotrexate:&#xD;
&#xD;
               -  Abnormal renal function, defined as serum creatinine &gt;142 µmol/L in women and&#xD;
                  &gt;168 µmol/L in men, or a glomeruli filtration rate (GFR) &lt;40 mL/min/1.73 m2.&#xD;
&#xD;
               -  Abnormal liver function, defined as transaminases above the upper normal limit,&#xD;
                  active or previous hepatitis B or C infection, or known cirrhosis&#xD;
&#xD;
               -  Lung fibrosis (maximum 6 months old x-ray), active infection, or reduced&#xD;
                  hematopoiesis (i.e. anemia, leukopenia and/or thrombocytopenia).&#xD;
&#xD;
               -  Planned pregnancy within 18 months after screening (men/women), and pregnancy,&#xD;
                  breastfeeding, or insufficient anti-conception therapy for female fertile&#xD;
                  participants. Contraception should be maintained during treatment and until the&#xD;
                  end of systemic exposure, i.e. 3 months after methotrexate discontinuation.&#xD;
                  Sufficient anti-conception therapy consists of intra-uterine device (coil) or&#xD;
                  hormonal anti-conception (birth control pills, implant, intra-uterine system,&#xD;
                  dermal patch, vaginal ring, or injections).&#xD;
&#xD;
               -  Alcohol or other drug abuse in the last year.&#xD;
&#xD;
               -  Intolerance to lactose.&#xD;
&#xD;
          -  Chronic inflammatory rheumatic diseases (such as rheumatoid arthritis and psoriatic&#xD;
             arthritis or gout), active inflammatory bowel disease, or positive rheumatoid factor&#xD;
             or anti-CCP antibodies.&#xD;
&#xD;
          -  Other severe co-morbidities such as hemochromatosis, fibromyalgia, psoriasis, blood&#xD;
             dyscrasias, and coagulation disorders, history of malignancy (except successfully&#xD;
             treated squamous or basal cell skin carcinoma), uncontrolled diabetes mellitus, severe&#xD;
             hypertension, unstable ischemic heart disease, severe heart failure, severe pulmonary&#xD;
             disease, severe and/or opportunistic infections and/or chronic infections, active&#xD;
             tuberculosis, positive human immunodeficiency virus (HIV) status, recent stroke, bone&#xD;
             marrow hypoplasia, or demyelinating diseases of the central nervous system.&#xD;
&#xD;
          -  Other likely causes of hand symptoms: thoracic outlet syndrome, carpal tunnel disease,&#xD;
             diabetic cheiropathy, injury in finger joints previous 6 months, or palmar&#xD;
             tenosynovitis/trigger finger.&#xD;
&#xD;
          -  Oral or intra-muscular steroids in the previous month&#xD;
&#xD;
          -  Intra-articular treatments or aspirations of any kind of any joint in the hands 3&#xD;
             months before inclusion&#xD;
&#xD;
          -  Analgesics or NSAIDs, unless stable dosage for ≥1 month.&#xD;
&#xD;
          -  Symptomatic slow-acting drugs for OA (SYSADOA), unless stable dose for ≥3 months and&#xD;
             require stable dose throughout the study.&#xD;
&#xD;
          -  Disease-modifying osteoarthritis drugs (DMOADs) previous three months.&#xD;
&#xD;
          -  Scheduled hand surgery during study participation.&#xD;
&#xD;
          -  Planning to start other treatments for hand OA in the study participation period.&#xD;
&#xD;
          -  Not able to adhere to the study visit schedule and protocol requirements.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore K Kvien, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Professor Em.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ida K. Haugen, MD, PhD</last_name>
    <phone>95859884</phone>
    <email>ida.k.haugen@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alexander Mathiessen, MD, PhD</last_name>
    <phone>97501889</phone>
    <email>alexander_mathiessen@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Diakonhjemmet Hospital</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ida K Haugen, MD, PhD</last_name>
      <phone>+47 95859884</phone>
      <email>ida.k.haugen@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 22, 2020</study_first_submitted>
  <study_first_submitted_qc>October 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diakonhjemmet Hospital</investigator_affiliation>
    <investigator_full_name>Ida Kristin Haugen</investigator_full_name>
    <investigator_title>Senior researcher, doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The trialists and other study personnel that conceive of the study, and then plan, manage, monitor, analyze and publish it, will have access to IPD. Participants' identification code numbers are de-identified by replacing the original code number with a new random code number. Only the PI and project coordinator have access to this code.&#xD;
The protocol, SAP, ICF, and CSR will be shared with regulatory agents as required.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://drive.google.com/file/d/1AKuis2zJlqhUqY4OEPyVhQPpIiuPnnhr/view?usp=sharing</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://drive.google.com/file/d/1mB2pEgRmuMhaVM_eNnnyXdqsyev4wev5/view?usp=sharing</doc_url>
    </study_doc>
    <study_doc>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://drive.google.com/file/d/1oE_9J-5uwLpboVWEsUJL6tHn4st1ea9r/view?usp=sharing</doc_url>
    </study_doc>
  </study_docs>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

